ASAhmed M. Salem

Ahmed M. Salem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmed M. Salem has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Let-7a and miR-34a Interplay Potent Suppressive Roles in Hepatocellular Carcinoma via Co-Targeting FNDC3B, IGF2 and SOX4

    by Bangly Soliman, Ahmed Fawzy Ibrahim, Ahmed Salem, Mohamed Ghazy, Mahmoud T. Abo-Elfadl, Mahmoud ElHefnawi, Mario Flores

    Both let-7a and miR-34a have been repeatedly studied as pivotal suppressors for Hepatocellular carcinoma; however, their combined regulations remain to be fully elucidated. In the present study, we performed a comprehensive in silico analysis for let-7a and miR-34a using a wealth of updated tools: miRWalk, Genetrail and miRnet. In addition, our study is the first to quantify both miRs and their three predicted yet not experimentally validated oncogenic targets: FNDC3B, IGF2 and SOX4. This was assessed in HepG2 cell model following treatment by PEGP-vector expressing the miRs by MTT assay, florescence microscopy, qPCR and immune-florescence. Our bioinformatics analysis revealed a pool of common predicted hepatocarcinogenic targets shared by both let-7a and miR-34a. Importantly, three targets were identified as co-regulated through multiple canonical binding sites for each miR, and these had not been experimentally validated before. Furthermore, functional enrichment of these putative targets demonstrated their significant involvement in major and emerging HCC hallmarks, such as reprogramming of energy metabolism and evading immune destruction. These findings support our concept of simultaneous co-regulation of these oncogenes through the signaling networks and GO terms associated with both miRs. Consistently, our experimental results verified the significant overexpression of both miRs in HepG2 cells, leading to reduced tumor cell proliferation and decreased levels of the three oncogenic transcripts. Interestingly, miR-34a exhibited a superior suppression effect, reaching 38.7%, and SOX4 was identified as the most significantly downregulated target at both transcriptional and translational levels. Our findings provide new insights into the interconnected anti-HCC effects of let-7a and miR-34a and highlight the potential of applying their combined use to achieve the best therapeutic outcomes for this invasive tumor.


  • Effect of galectin-3 inhibition on hepatocyte nuclear factors 4α and 1α expression in liver after acetaminophen long-term induced toxicity.

    by Mahmoud A. Abdel-Monem, Ahmed M. Salem, Karam A. Mahdy, Gamila S.M. El-Saeed, Abdel-Razik H. Farrag, Nahla S. Hassan

    Acetaminophen (APAP) induced liver injury can occur through acute or repeated administration of high doses. Hepatocyte nuclear factors HNF4α and HNF1α are key transcription factors involved in regulating the expression of drug metabolism enzymes and are affected by proinflammatory cytokines. Meanwhile galectin-3 (Gal-3) is a β-galactoside-binding lectin implicated in the regulation of macrophage activation and secretion of inflammatory mediators. This study aimed to evaluate the impact of galectin-3 inhibition on HNF4α and HNF1α gene expression after long-term administration of APAP, and to investigate the resulted effect on APAP induced hepatotoxicity. The study was performed on thirty two Wistar rats divided equally into four groups; control group, modified citrus pectin (MCP) (Gal-3 inhibitor) receiving group, APAP receiving group, and APAP plus MCP receiving group. APAP induced inhibition of liver HNF4α and HNF1α gene expression, and elevation of liver Gal-3 and tumor necrosis factor- α levels (TNF-α), depletion of reduced glutathione and its maintaining enzymes, besides elevation in levels of serum liver function parameters and appearance of necrotic areas in the liver. Gal-3 inhibition preserved HNF4α and HNF1α gene expression, TNF-α, and each of reduced glutathione and its maintaining enzymes near normal levels. It also significantly reduced APAP induced hepatotoxicity.

  • Open Access

    Vitamin D levels and vitamin D receptor genetic variants in Egyptian cardiovascular disease patients with and without diabetes

    by Soad M. Eweida, Ahmed Salem, Yehia M. Shaker, Nervana Samy, Ibrahim Yassen, Rania Hassan Mohamed

    Background: 25-Hydroxyvitamin D (Vit.D) levels associated with cardiovascular disease (CVD) may vary according to genetic variants in the vitamin D receptor (VDR) gene. However, the existing results are not conclusive in the Egyptian population, where diabetes mellitus is a common CVD risk factor. The purpose of the study was to evaluate the role of VDR polymorphism in Egyptian patients with CVD by studying the association of the rs2228570 (FokI) and rs1544410 (BsmI) single nucleotide polymorphisms (SNPs) of the VDR gene and serum levels of Vit.D with several CVD risk factors in patients with and without diabetes mellitus. We studied the genotypes for rs2228570 (FokI) and rs1544410 (BsmI) SNPs of the VDR gene in 382 Egyptian patients (120 CVD patients with diabetes, 124 CVD patients without diabetes, 69 diabetic patients without CVD and 69 healthy individuals). We also determined the serum levels of Vit.D, insulin, lipids, fasting blood glucose (FBG), and the body mass index (BMI). Results: The distribution of genotypes and allelic frequencies of the rs2228570 (FokI) and rs1544410 (BsmI) SNPs of the VDR gene was significant in CVD patients (p < 0.001). The level of Vit.D was significantly lower in patients with CVD and diabetes compared to those without diabetes (p < 0.001). Moreover, there was a significant association between Vit.D level and the selected SNPs with serum lipids, BMI, FBG, and insulin levels in CVD patients with or without diabetes. Conclusion: The level of Vit.D and the distribution of VDR polymorphisms are associated with risk of CVD in Egyptian patients with or without diabetes. These results suggest that VDR polymorphisms may be potential diagnostic biomarkers for CVD susceptibility.


  • Open Access

    Astragalus membranaceus and Punica granatum alleviate infertility and kidney dysfunction induced by aging in male rats

    by Ameera S. Alshinnawy, Wael M. El-Sayed, AlShaimaa M. TAHA, Ahmed A. Sayed, Ahmed M. Salem

    By aging, male fertility and kidney function decline. Therefore, the investigation of health span-extending agents becomes more urgent to overcome aging-induced infertility and kidney dysfunction. The current research was undertaken to investigate the antiaging efficacy of Astragalus membranaceus telomerase activator-65 (Ta-65) and pomegranate supplements. Forty male Wistar rats were divided into young rats, aged rats, aged rats treated with Ta-65 (500mg/kg/day), and aged rats treated with pomegranate (250mg/kg/day). Testosterone, FSH, LH, and kidney functions were measured in serum. Sperm analysis as well as testicular histological examination was performed. Aging caused an imbalance in male sex hormones resulting in sperm abnormality and reductions in the sperm count and motility. Elevations in serum creatinine, uric acid, sodium, and potassium were reported in aged rats. Treatment with Ta-65 or pomegranate effectively ameliorated all the deteriorations induced by normal aging in male fertility and renal function. Ta-65 and pomegranate possessed strong antiaging activity by alleviating aging-induced male infertility through reestablishing the hormonal balance and testis architecture. They also alleviated the kidney dysfunction. On comparing Ta-65 with pomegranate, the improvement in FSH, LH, and sperm abnormalities caused by Ta-65 was much better than that caused by pomegranate.


  • Open Access

    Modulatory effect of Prosopis juliflora leaves on hepatic fibrogenic and fibrolytic alterations induced in rats by thioacetamide

    by Salah M. Hassan, AlShaimaa M. Taha, Omayma A. Eldahshan, Ahmed A. Sayed, Ahmed M. Salem


  • Purification and biochemical characterization of peroxidase isoenzymes from Ficus carica latex

    by Alshaimaa M. Elsayed, Usama M. Hegazy, Marwa G.A. Hegazy, Somia S. Abdel-Ghany, Walaa H. Salama, Ahmed M.H. Salem, Afaf S. Fahmy


  • Neuroprotective and Therapeutic Effect of Caffeine on the Rat Model of Parkinson's Disease Induced by Rotenone

    by Yasser A. Khadrawy, Ahmed M. Salem, Karima A. El-Shamy, Emad K. Ahmed, Nevein N. Fadl, Eman N. Hosny

    The present study aimed to investigate the protective and therapeutic effects of caffeine on rotenone-induced rat model of Parkinson's disease (PD). Rats were divided into control, PD model induced by rotenone (1.5 mg/kg intraperitoneally (i.p.) for 45 days), protected group injected with caffeine (30 mg/kg, i.p.) and rotenone for 45 days (during the development of PD model), and treated group injected with caffeine (30 mg/kg, i.p.) for 45 days after induction of PD model. The data revealed a state of oxidative and nitrosative stress in the midbrain and the striatum of animal model of PD as indicated from the increased lipid peroxidation and nitric oxide levels and the decreased reduced glutathione level and activities of glutathione-S-transferase and superoxide dismutase. Rotenone induced a decrease in acetylcholinesterase and Na+/K+-ATPase activities and an increase in tumor necrosis factor-α level in the midbrain and the striatum. Protection and treatment with caffeine ameliorated the oxidative stress and the changes in acetylcholinesterase and Na+/K+-ATPase activities induced by rotenone in the midbrain and the striatum. This was associated with improvement in the histopathological changes induced in the two areas of PD model. Caffeine protection and treatment restored the depletion of midbrain and striatal dopamine induced by rotenone and prevented decline in motor activities (assessed by open field test) and muscular strength (assessed by traction and hanging tests) and improved norepinephrine level in the two areas. The present study showed that caffeine offered a significant neuroprotection and treatment against neurochemical, histopathological, and behavioral changes in a rotenone-induced rat model of PD.


  • Biochemical Characterization of Buffalo Liver Glucose-6-Phosphate Dehydrogenase Isoforms

    by Mahmoud A. Ibrahim, Abdel-Hady M. Ghazy, Ahmed M. H. Salem, Mohamed A. Ghazy, Mohammed M. Abdel-Monsef

    Glucose-6-phosphate dehydrogenase (G6PD) is a key regulatory enzyme involved in the pentose phosphate pathway. This works represents purification of two buffalo liver glucose-6-phosphate dehydrogenases (BLG6PD1 and BLG6PD2) using combination of ammonium sulfate precipitation and several chromatographic columns. Both enzymes (BLG6PD1 and BLG6PD2) were homogenous on both native PAGE as well as 12 % SDS PAGE with molecular weights of 28 and 66 kDa. The molecular weight of BLG6PD1 and BLG6PD2 native forms were determined to be 28 and 66 kDa by gel filtration; indicating monomeric proteins. The K m values for BLG6PD1 and BLG6PD2 estimated to be 0.059 and 0.06 mM of β-nicotinamide adenine dinucleotide phosphate. The optimum activity of BLG6PD1 and BLG6PD2 were displayed at pH 8.0 and 8.2 with an isoelectric point (pI) of pH 7.7–7.9 and 5.7–5.9. The divalent cations MgCl2, and CoCl2 act as activators, on the other hand, FeCl2, CuCl2 and ZnCl2 are potent inhibitors of BLG6PD1 and BLG6PD2 activity. NADPH inhibited both isoenzymes competitively with Ki values of 0.012 and 0.030 mM. This study describes a reproducible purification scheme of G6PD from the liver of buffalo as a rich source.


  • Open Access

    Purification and Characterization of Glucose-6-Phosphate Dehydrogenase from Camel Liver

    by Mahmoud A. Ibrahim, Abdel-Hady M. Ghazy, Ahmed M. H. Salem, Mohamed A. Ghazy, Mohamed M. Abdel-Monsef

    Glucose-6-phosphate dehydrogenase from camel liver was purified to homogeneity by ammonium sulfate precipitation and a combination of DEAE-cellulose, Sephacryl S-300 gel filtration, and 2, 5 ADP Sepharose 4B affinity chromatography columns. The specific activity of camel liver G6PD is increased to 1.80438 units/mg proteins with 63-fold purification. It turned out to be homogenous on both native PAGE and 12% SDS PAGE, with a molecular weight of 64kDa. The molecular weight of the native form of camel liver G6PD was determined to be 194kDa by gel filtration indicating a trimeric protein. The value was found to be 0.081mM of NADP


  • Retracted

    RETRACTED: Potential of bone marrow mesenchymal stem cells in management of Alzheimer's disease in female rats

    by Ahmed M. Salem, Hanaa H. Ahmed, Hazem M. Atta, Mohamed A. Ghazy, Hadeer A. Aglan

    Alzheimer's disease (AD) has been called the disease of the century with significant clinical and socioeconomic impacts. Pharmacological treatment has limited efficacy and only provides symptomatic relief without long-term cure. Accordingly, there is an urgent need to develop novel and effective medications for AD. Stem cell-based therapy is a promising approach to handling neurodegenerative diseases. Therefore, the current study aimed to explore the possible therapeutic role of single intravenous injection of bone marrow derived mesenchymal stem cells (BM-MSCs) after 4 months in management of AD in the experimental model. The work also extended to compare the therapeutic potential of BM-MSCs with 2 conventional therapies of AD; rivastigmine and cerebrolysin administered daily. BM-MSCs were able to home at the injured brains and produced significant increases in the number of positive cells for choline acetyltransferase (ChAT) and survivin expression, as well as selective AD indicator-1 (seladin-1) and nestin gene expression. Histopathological examination indicated that BM-MSCs could remove beta-amyloid plaques from hippocampus. Significant improvement in these biomarkers was similar to or better sometimes than the reference drugs, clearly showing the potential therapeutic role of BM-MSCs against AD through their anti-apoptotic, neurogenic and immunomodulatory properties.